Poolbeg Pharma PLC
POLBF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$73.14M
Close$
$0.02
82.2% downside
Current Fair Value
82.2% downsideOvervalued by 82.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $73.14 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.01 |
| Beta | 1.81 |
| Outstanding Shares | 703,662,758 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -8.85 |
|---|---|
| PEG | 80.95 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
September 29, 2026
EPS Estimate
$-0.00
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Poolbeg Pharma PLC
15 employees
CEO: Jeremy Skillington
Poolbeg Pharma plc operates as a clinical-stage pharmaceutical company, headquartered in London, United Kingdom, with a focus on developing treatments for infectious diseases. Its current product pipeline includes: POLB 001: A p38 MAP Ki...